Abstract
Lenvatinib significantly prolonged progression-free survival versus placebo in patients with radio-iodine refractory differentiated thyroid carcinoma. However, the primary adverse effects of any grade that occurred in >40% of patients in the lenvatinib group of the Phase III SELECT trial was hypertension (67.8%). Therefore, this drug should be used with caution in patients with cardiological morbidity. Here, we describe the case of a 73-year-old man with hypertension, obesity and chronic atrial fibrillation, who received lenvatinib for 6 months in the absence of cardiological symptoms.
Keywords:
cardiological comorbidity; lenvatinib; papillary thyroid cancer; tyrosine kinase inhibitor.
MeSH terms
-
Aged
-
Cardiovascular Abnormalities / complications
-
Cardiovascular Abnormalities / diagnostic imaging
-
Cardiovascular Abnormalities / drug therapy*
-
Cardiovascular Abnormalities / pathology
-
Combined Modality Therapy
-
Humans
-
Hypertension / chemically induced
-
Hypertension / diagnostic imaging
-
Hypertension / drug therapy*
-
Hypertension / pathology
-
Male
-
Phenylurea Compounds / administration & dosage*
-
Phenylurea Compounds / adverse effects
-
Positron Emission Tomography Computed Tomography
-
Quinolines / administration & dosage*
-
Quinolines / adverse effects
-
Radiofrequency Ablation / methods
-
Thyroid Cancer, Papillary / complications
-
Thyroid Cancer, Papillary / diagnostic imaging
-
Thyroid Cancer, Papillary / drug therapy*
-
Thyroid Cancer, Papillary / pathology
Substances
-
Phenylurea Compounds
-
Quinolines
-
lenvatinib